Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease"

Affiliations

Comment

Xiaodong Yang et al. Mov Disord. 2023 Apr.

. 2023 Apr;38(4):711.

doi: 10.1002/mds.29368.

¹ Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

No abstract available

Comment on

Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
Yang X, Ai P, He X, Mo C, Zhang Y, Xu S, Lai Y, Qian Y, Xiao Q. Yang X, et al. Mov Disord. 2022 Aug;37(8):1634-1643. doi: 10.1002/mds.29063. Epub 2022 May 24. Mov Disord. 2022. PMID: 35607987
Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
Müller T, Kuhn W. Müller T, et al. Mov Disord. 2023 Apr;38(4):710-711. doi: 10.1002/mds.29365. Mov Disord. 2023. PMID: 37061885 No abstract available.

1. Yang X, Ai P, He X, et al. Parkinson's disease is associated with impaired gut-blood barrier for short-chain fatty acids. Mov Disord 2022;37:1634-1643.
1. Shin C, Lim Y, Lim H, Ahn TB. Plasma short-chain fatty acids in patients with Parkinson's disease. Mov Disord 2020;35:1021-1027.
1. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord 2016;32:66-72.
1. Hill-Burns EM, Debelius JW, Morton JT, et al. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord 2017;32:739-749.
1. Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science 2019;364:eaau6323.